Merja Perala
Overview
Explore the profile of Merja Perala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1321
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang W, Schmitz A, Kallionpaa R, Perala M, Pitkanen N, Tukiainen M, et al.
Acta Oncol
. 2024 Jul;
63:542-551.
PMID: 38967220
Background: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers. Using the Auria Biobank in Finland, we aimed to identify and characterize patients with these gene fusions, and describe...
2.
Zhang W, Schmitz A, Kallionpaa R, Perala M, Pitkanen N, Tukiainen M, et al.
Oncotarget
. 2024 Feb;
15:106-116.
PMID: 38329731
Selective tropomyosin receptor kinase (TRK) inhibitors are approved targeted therapies for patients with solid tumors harboring a neurotrophic tyrosine receptor kinase () gene fusion. Country-specific estimates of gene fusion frequency,...
3.
Rodosthenous R, Niemi M, Kallio L, Perala M, Terho P, Knopp T, et al.
BMJ Open
. 2022 Oct;
12(10):e064695.
PMID: 36198465
Objectives: To recontact biobank participants and collect cognitive, behavioural and lifestyle information via a secure online platform. Design: Biobank-based recontacting pilot study. Setting: Three Finnish biobanks (Helsinki, Auria, Tampere) recruiting...
4.
Snellman A, Ekblad L, Koivumaki M, Lindgren N, Tuisku J, Perala M, et al.
Front Neurol
. 2022 Feb;
13:826423.
PMID: 35222254
Background: Detailed characterization of early pathophysiological changes in preclinical Alzheimer's disease (AD) is necessary to enable development of correctly targeted and timed disease-modifying treatments. ASIC-E4 study ("Beta-Amyloid, Synaptic loss, Inflammation...
5.
Khan M, Khaznadar S, Routila J, Ventela S, Schmid E, Gebhart B, et al.
Head Neck
. 2020 Jan;
42(4):625-635.
PMID: 31919967
Background: MET has emerged as target in head and neck squamous cell carcinoma (HNSCC). However, clinical data on MET inhibition in HNSCC are limited. Methods: HNSCC biopsies and cell lines...
6.
de Vera C, Diaz Crespin G, Hernandez Daranas A, Montalvao Looga S, Lillsunde K, Tammela P, et al.
Mar Drugs
. 2018 Sep;
16(9).
PMID: 30200664
The study of marine natural products for their bioactive potential has gained strength in recent years. Oceans harbor a vast variety of organisms that offer a biological and chemical diversity...
7.
Jernstrom S, Hongisto V, Leivonen S, Due E, Tadele D, Edgren H, et al.
Breast Cancer (Dove Med Press)
. 2017 Mar;
9:185-198.
PMID: 28356768
Background: Approximately 15%-20% of all diagnosed breast cancers are characterized by amplified and overexpressed HER2 (= ErbB2). These breast cancers are aggressive and have a poor prognosis. Although improvements in...
8.
Jacquemet G, Baghirov H, Georgiadou M, Sihto H, Peuhu E, Cettour-Janet P, et al.
Nat Commun
. 2016 Dec;
7:13297.
PMID: 27910855
Mounting in vitro, in vivo and clinical evidence suggest an important role for filopodia in driving cancer cell invasion. Using a high-throughput microscopic-based drug screen, we identify FDA-approved calcium channel...
9.
Cantisani M, Parascandolo A, Perala M, Allocca C, Fey V, Sahlberg N, et al.
Oncotarget
. 2016 Apr;
7(19):28510-22.
PMID: 27058903
RET, BRAF and other protein kinases have been identified as major molecular players in thyroid cancer. To identify novel kinases required for the viability of thyroid carcinoma cells, we performed...
10.
Montalvao S, Demirel Z, Devi P, Lombardi V, Hongisto V, Perala M, et al.
N Biotechnol
. 2016 Feb;
33(3):399-406.
PMID: 26902670
Marine organisms constitute approximately one-half of the total global biodiversity, being rich reservoirs of structurally diverse biofunctional components. The potential of cyanobacteria, micro- and macroalgae as sources of antimicrobial, antitumoral,...